Primrose Bio offers mRNA manufacturing solutions for RNA-based vaccines and therapeutics, including both ready-to-use and custom Prima RNApols™ designed to improve mRNA synthesis and in vitro transcription (IVT) consistency. Built on deep enzyme engineering and manufacturing expertise, Prima RNApols give mRNA developers greater control over yield and product quality with reduced input requirements. This delivers predictable IVT performance during process development at lower cost.

The Prima RNApols portfolio is designed to meet a range of program needs and DNA template requirements. Ready-to-use Prima RNApols are validated, consistent, and available in reagent and GMP-grades for rapid product development. For programs with more specific requirements, Primrose collaborates closely with partners to design custom RNA polymerases tailored to defined quality attributes, cost targets, and manufacturing objectives. This dual approach gives teams the right balance of speed, customization, and performance.

Prima RNApols are built for demanding mRNA applications, including long templates and self-amplifying RNA. Polymerase choice strongly impacts yield, dsRNA levels, and capping efficiency. By reducing dsRNA and other reaction byproducts while improving reagent efficiency, Prima RNApols can simplify downstream processing and improve overall process economics.

Together, the Prima RNApols portfolio reduces variability, aligns enzyme performance with target product profiles, and expands the range of mRNA constructs that can be manufactured reliably at scale.